Diabetes drug helps reduce rate of strokes

Researchers for Takeda Pharmaceuticals says that a new analysis of a year-old study of Actos demonstrates that patients with type 2 diabetes and a history of one stroke reduce their chances of a second stroke by 47 percent by taking the drug. Volunteers who added Actos to standard therapy saw the rate of second strokes drop from 10.2 percent in a placebo group to 5.6 percent. Researchers added that there was no apparent difference in stroke rates among patients who had never had a prior stroke. Actos makes the cells of patients with type 2 diabetes more sensitive to insulin, allowing a better response to their own naturally produced insulin. The new data comes from existing data drawn from a large clinical study that was completed a year ago.

- read the report on Actos from TradeArabia

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.